Association of main demographic and clinical variables with loss of remission and disease flare in patients with axSpA in remission with anti-TNF-α therapy. Values are median (IQR) or n (%) unless otherwise specified.
| Variables | Loss of Remission | Disease Flare | ||||
|---|---|---|---|---|---|---|
| Yes, n = 37 | No, n = 137 | p | Yes, n = 28 | No, n = 146 | p | |
| Male vs female | 28 (75.7) | 105 (76.6) | 0.902 | 22 (78.6) | 111 (76) | 0.771 |
| Age, yrs, mean (SD) | 44.1 (13.5) | 43.1 (12.6) | 0.699 | 44.2 (13.9) | 43.1 (12.5) | 0.662 |
| Disease duration, mos | 108 (36–192) | 82 (36–155) | 0.289 | 88 (36–153) | 84 (36–168) | 0.732 |
| ESR, mm/h | 12 (10–19) | 7 (4–12) | 0.001 | 12 (9–19) | 7 (4–13) | 0.001 |
| CRP, mg/dl | 0.5 (0.2–0.6) | 0.2 (0.03–0.5) | 0.010 | 0.5 (0.2–0.6) | 0.2 (0.05–0.5) | 0.022 |
| NSAID, concomitant use vs sporadic use | 9 (24.3) | 12 (8.9) | 0.011 | 8 (28.6) | 13 (9) | 0.004 |
| HLA-B27, presence vs absence | 28 (75.7) | 94 (68.6) | 0.405 | 21 (75) | 101 (69.2) | 0.538 |
| ASDAS-CRP | 1.22 (0.88–1.62) | 0.98 (0.42–1.51) | 0.107 | 1.28 (0.91–1.65) | 0.99 (0.42–1.51) | 0.056 |
| ASDAS-CRP > 0.8 vs ≤ 0.8 | 29 (78.4) | 78 (57.8) | 0.022 | 23 (82.1) | 84 (58.3) | 0.017 |
| EAM, presence vs absence | 12 (32.4) | 43 (31.4) | 0.903 | 9 (32.1) | 46 (31.5) | 0.947 |
axSpA: axial spondyloarthritis; TNF-α: tumor necrosis factor-α; IQR: interquartile range; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; NSAID: nonsteroidal antiinflammatory drugs; ASDAS: Ankylosing Spondylitis Disease Activity Score; EAM: extraarticular manifestations.